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Introduction 
Plasmablastic lymphoma (PBL) is a rare, aggressive 
malignancy that was initially described in 1997 [1]. 
There have been approximately 250 reported cases 
in the literature since then [1]. Most patients who 
develop PBL are immunosuppressed, particularly 
owing to HIV infection (69% of cases), [2]. HIV-
associated PBL is found more commonly in men (3:1 
M:F) with a median age of onset of 39-42 years old [3, 
4]. The overwhelming majority (95%) of HIV-
associated PBL cases present with extranodal 
involvement, most commonly the oral cavity (48%) 
and the gastrointestinal tract (12%), [2]. However, a 
small minority (6%) of patients with PBL present 
initially with skin complaints. We describe an HIV-
positive man with PBL that presented as nodules and 
ulcers on the legs. 
 
Case Synopsis 
A 53-year-old, man with HIV/AIDS, heart failure, 
venous stasis dermatitis, and recent right leg 
amputation for osteomyelitis was evaluated for a 
two month history of left lower extremity pain and 
ulceration. His physical examination was notable for 
2+ edema, yellow hyperkeratotic plaques, multiple 
small ulcers, and violaceous exophytic nodules on 
the left anterior and medial lower extremity (Figure 
1). No other skin or mucosal lesions were noted. He 
denied fever, chills, night sweats, or a personal or 
family history of skin cancer. He underwent extensive 
laboratory studies that were notable for the 
following: WBC: 1.1 (4.0–10.3 x109 cells/L); Hgb: 7.0 
(13.0–17.0 g/dL); platelets: 115.0 (160.0–380.0 x 109 
cells/L); CD4: 81.0 (200.0–1400.0 cells/mcL); Ig kappa 
free light chains: 7.6 (0.3–1.9 mg/dL); Ig lambda free 
light chains: 3.5 (0.6–2.6 mg/dL); kappa/lambda 2.2 
(0.3–1.7); UPEP with no M-spike. 
Computed tomography scans of the head, neck, 
chest, and abdomen/pelvis demonstrated 
splenomegaly and multiple non-enlarged para-
aortic and iliac lymph nodes. A bone marrow biopsy 
was negative for a hematolymphoid malignancy. A 
skin biopsy was performed (Figure 2) and found 
Abstract 
Plasmablastic lymphoma (PBL) is a rare and 
aggressive malignancy associated with 
immunosuppression and the oncogenic effects of 
the Epstein-Barr virus (EBV). We present an HIV-
positive man with PBL that presented as ulcers and 
violaceous exophytic nodules on the legs. The clinical 
features, histologic appearance, and differential 
diagnosis of this malignancy are briefly reviewed.  
Figure 1. A) Left lower extremity demonstrating a diffuse 
violaceous, yellow-brown coalescing hyperkeratotic plaques, 
ulcers, and exophytic violaceous nodules on the anterior and
medial surfaces. B) Close-up photograph of the left shin
demonstrating an ulcerated, violaceous nodule. 
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atypical enlarged immunoblastic cells, plasma cells, 
apoptotic bodies, and mitotic figures in the dermis. 
Immunostaining was positive for CD138, CD38, 
MUM1, and CD56. Tumor cells were negative for 
CD20, CD2, CD3, CD4, S-100, CD34, desmin, CD34, 
and HHV8. In-situ hybridization was positive for EBV 
and a kappa light chain restriction. 
 
Case Discussion 
The differential diagnosis for exophytic violaceous 
skin nodules in an HIV positive individual is broad 
and includes angiosarcoma, Kaposi sarcoma, B-cell 
lymphomas, fungal infections, and mycobacterial 
infections. Within the category of B-cell lymphomas, 
a rare and highly aggressive cause is plasmablastic 
lymphoma. 
Plasmablastic lymphoma is a high-grade malignancy 
characterized by proliferation of large 
immunoblastic-appearing cells with centrally-
located, round nuclei with prominent eosinophilic 
nucleoli. Some tumors exhibit a histomorphology 
displaying more obvious plasmacytic differentiation 
with eccentric nuclei with ample basophilic 
cytoplasm and eosinophilic perinuclear hof [3]. 
Mitotic figures are generally abundant and the 
presence of numerous scavenger macrophages 
imparts a characteristic starry sky appearance to the  
neoplastic infiltrate. Immunohistochemistry is key to 
the diagnosis, with PBL generally staining positive 
for multiple plasma cell markers including CD79a, 
MUM-1, BLIMP-1, CD38, and CD138, but not the B-
cell markers CD19 or CD20 [2]. Kappa and lambda 
studies show a monotypic light chain restriction. 
Plasmablastic lymphoma is difficult to differentiate 
from plasmablastic/anaplastic multiple myeloma on 
biopsy as they have identical histomorphology and 
immunophenotype. However, the presence of EBV 
strongly favors PBL. If present, paraproteinemia, 
hypercalcemia, lytic bone lesions, and 
immunocompetence favor multiple myeloma. In 
contrast to plasmablastic lymphoma and multiple 
myeloma, diffuse large B-cell lymphoma is CD20 
positive. Rare cases of PBL positive for human 
herpesvirus 8 have been reported, a variant closely 
related to plasmablastic multicentric Castleman 
disease [5]. The pathogenesis of PBL is debated, but 
it is believed to be related to the oncogenic effects of 
EBV infection on B-cells and Myc gene arrangements. 
EBV is found in 70-75% of cases [2, 4], whereas Myc 
gene rearrangements are found in 67% [4]. 
Plasmablastic lymphoma is treated with immune 
reconstitution and chemotherapy but is 
characterized by early chemotherapy resistance. 
Stage of disease at presentation is strongly 
correlated with survival; 50% of patients with stage 1  
 
Figure 2. Skin biopsy. A) Solid arrows indicate enlarged immunoblastic cells while unfilled arrows point at plasma cells. H&E, 40×. B) Solid 
arrows point at cells showing strong nuclear positivity for Epstein Barr virus by in-situ hybridization, 40×. 
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disease (single lymph node region) remain alive at 30 
months compared to 30% of those with stage 4 
disease (diffuse involvement of extralymphatic 
organs), [3]. Untreated patients have a median 
survival of around four months if HIV negative and 
three months if HIV positive [6]. Median survival 
increases to 16 months in patients who receive 
chemotherapy [6]. Our patient was started on 
chemotherapy (cyclophosphamide, vincristine, 
prednisolone, and bortezomib) and highly-active 
antiretroviral therapy, but unfortunately passed 
away one month after initiation of chemotherapy. 
 
Conclusion 
Plasmablastic lymphoma is a rare malignancy 
associated with immunosuppression that may 
present first to the dermatologist. Given the 
aggressive clinical course of PBL, it is important that 
dermatologists consider PBL in the differential 
diagnosis for rapidly growing nodules and ulcers in 
an immunosuppressed patient. 
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